Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the ...

That said, history suggests that Pfizer will be in a much better position in five years than it is today. The aggressive ...

When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options.

Dividend stocks can be a good strategy for investors seeking a reliable and potentially more predictable stream of passive ...

Pfizer is currently a high-yield quality stock trading at reasonable valuations, indicating a margin of safety that surely curtails investment risks. With the stock market subject to bouts of ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

Two industry-leading businesses are ideally positioned to announce and complete their respective first-ever splits.